Exon-Level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Bemmo, Amandine ^a   Dias, Christel ^a   Rose, April A N Rose ^a   Russo, Caterina ^a   Siegel, Peter ^a   Majewski, Jacek ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTOME; MESSENGER RNA; UNTRANSLATED RNA;

ALTERNATIVE RNA SPLICING; ANGPT2 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BTG1 GENE; CANCER STAGING; CCNT2 GENE; CD44 GENE; CELL DEATH; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION; GENETIC DISORDER; HPRT1 GENE; INTRON; ITGB1 GENE; LUNG METASTASIS; MAPK14 GENE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHB GENE; SLK GENE; TUMOR GENE; ANIMAL; BREAST TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; METASTASIS; METHODOLOGY; PATHOLOGY; PHENOTYPE; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; TUMOR CELL LINE;

MURINAE;

ALTERNATIVE SPLICING; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EXONS; FEMALE; GENE EXPRESSION PROFILING; MICE; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; RNA, UNTRANSLATED;

EID: 77957772409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011981     Document Type: Article

References (77)

1. Weigelt B, Peterse JL, van't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591-602.
2. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, et al. (2008) Alternative isoform regulation in human tissue transcriptomes. Nature 456: 470-476.
3. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ (2008) Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 40: 1413-1415.
4. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, et al. (1993) Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608.
5. Martin SS, Ridgeway AG, Pinkas J, Lu Y, Reginato MJ, et al. (2004) A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23: 4641-4645.
6. Bourguignon LY, Gilad E, Rothman K, Peyrollier K (2005) Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1/estrogen receptor transcriptional activation, and ovarian cancer progression. J Biol Chem 280: 11961-11972.
7. Bourguignon LY, Singleton PA, Diedrich F, Stern R, Gilad E (2004) CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem 279: 26991-27007.
8. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, et al. (2003) Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v3. Cancer Res 63: 887-892.
9. Stickeler E, Kittrell F, Medina D, Berget SM (1999) Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 18: 3574-3582.
10. Cheng C, Sharp PA (2006) Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 26: 362-370.
11. Wallach-Dayan SB, Rubinstein AM, Hand C, Breuer R, Naor D (2008) DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol Cancer Ther 7: 1615-1623.
12. Venables JP (2006) Unbalanced alternative splicing and its significance in cancer. Bioessays 28: 378-386.
13. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, et al. (2006) Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 7: 325.
14. Kapur K, Xing Y, Ouyang Z, Wong WH (2007) Exon arrays provide accurate assessments of gene expression. Genome Biol 8: R82.
15. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, et al. (2008) Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7: 1214-1224.
16. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405.
17. Rose AA, Siegel PM (2007) Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer? Breast Cancer Res 9: 403.
18. Rose AA, Pepin F, Russo C, Abou Khalil JE, Hallett M, et al. (2007) Osteoactivin promotes breast cancer metastasis to bone. Mol Cancer Res 5: 1001-1014.
19. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al. (2002) The human genome browser at UCSC. Genome Res 12: 996-1006.
20. Mori Y, Sato F, Selaru FM, Olaru A, Perry K, et al. (2002) Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res 62: 3641-3645.
21. Johnson KW, Smith KA (1991) Molecular cloning of a novel human cdc2/CDC28-like protein kinase. J Biol Chem 266: 3402-3407.
22. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35: 211-231.
23. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ (2004) CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 64: 5702-5711.
24. Bates RC, Edwards NS, Burns GF, Fisher DE (2001) A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 61: 5275-5283.
25. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, et al. (2004) Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 23: 2996-3004.
26. Wang S, Nath N, Fusaro G, Chellappan S (1999) Rb and prohibitin target distinct regions of E2F1 for repression and respond to different upstream signals. Mol Cell Biol 19: 7447-7460.
27. Sato T, Saito H, Swensen J, Olifant A, Wood C, et al. (1992) The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer. Cancer Res 52: 1643-1646.
28. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 22: 153-183.
29. Gruber JJ, Zatechka DS, Sabin LR, Yong J, Lum JJ, et al. (2009) Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell 138: 328-339.
30. Meloche S, Pouyssegur J (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-3239.
31. Kronblad A, Hedenfalk I, Nilsson E, Pahlman S, Landberg G (2005) ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxiainduced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 24: 6835-6841.
32. Wong AS, Gumbiner BM (2003) Adhesion-independent mechanism for suppression of tumor cell invasion by E-cadherin. J Cell Biol 161: 1191-1203.
33. Bindels EM, Vermey M, van den Beemd R, Dinjens WN, Van Der Kwast TH (2000) E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ. Cancer Res 60: 177-183.
34. Luo J, Lubaroff DM, Hendrix MJ (1999) Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection. Cancer Res 59: 3552-3556.
35. Stockinger A, Eger A, Wolf J, Beug H, Foisner R (2001) E-cadherin regulates cell growth by modulating proliferation-dependent beta-catenin transcriptional activity. J Cell Biol 154: 1185-1196.
36. Brooks PC (1996) Cell adhesion molecules in angiogenesis. Cancer Metastasis Rev 15: 187-194.
37. McCormick BA, Zetter BR (1992) Adhesive interactions in angiogenesis and metastasis. Pharmacol Ther 53: 239-260.
38. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, et al. (2001) Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 98: 1853-1858.
39. Gilmore TD (2006) Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25: 6680-6684.
40. Brasier AR (2006) The NF-kappaB regulatory network. Cardiovasc Toxicol 6: 111-130.
41. Perkins ND (2007) Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8: 49-62.
42. Chiba N, Suldan Z, Freedman LP, Parvin JD (2000) Binding of liganded vitamin D receptor to the vitamin D receptor interacting protein coactivator complex induces interaction with RNA polymerase II holoenzyme. J Biol Chem 275: 10719-10722.
43. Qi X, Tang J, Pramanik R, Schultz RM, Shirasawa S, et al. (2004) P38 MAPK activation selectively induces cell death in K-ras-mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 279: 22138-22144.
44. Kent WJ (2002) BLAT-the BLAST-like alignment tool. Genome Res 12: 656-664.
45. Bemmo A, Benovoy D, Kwan T, Gaffney DJ, Jensen RV, et al. (2008) Gene expression and isoform variation analysis using Affymetrix Exon Arrays. BMC Genomics 9: 529.
46. Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, et al. (2010) Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70: 896-905.
47. Yip KW, Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406.
48. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, et al. (2005) Genomewide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24: 1348-1358.
49. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, et al. (2007) Homozygous deletions localize novel tumor suppressor genes in Bcell lymphomas. Blood 109: 271-280.
50. Muller-Pillasch F, Wallrapp C, Bartels K, Varga G, Friess H, et al. (1998) Cloning of a new Kunitz-type protease inhibitor with a putative transmembrane domain overexpressed in pancreatic cancer. Biochim Biophys Acta 1395: 88-95.
51. Dice LR (1945) Measures of the Amount of Ecologic Association Between Species. Ecology 26: 297-302.
52. Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, et al. (2008) Identification of alternative splicing markers for breast cancer. Cancer Res 68: 9525-9531.
53. Karlgren M, Ingelman-Sundberg M (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11: 61-67.
54. McKenzie EA (2007) Heparanase: a target for drug discovery in cancer and inflammation. Br J Pharmacol 151: 1-14.
55. Zhang L, Yang N, Liang S, Barchetti A, Vezzani C, et al. (2004) RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biol Ther 3: 1283-1289.
56. Duchaine TF, Slack FJ (2009) Rna interference and micro rna -oriented therapy in cancer: rationales, promises, and challenges. Curr Oncol 16: 61-66.
57. Affymetrix (2005) Guide to Probe Logarithmic Intensity Error (PLIER) Estimation.
58. Affymetrix (2006) Identifying and Validating Alternative Splicing Events.
59. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57: 289-300.
60. Rozen S, Skaletsky H.(2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365-386.
61. Fujii K, Fujii Y, Hubscher S, Tanaka Y (2001) CD44 is the physiological trigger of Fas up-regulation on rheumatoid synovial cells. J Immunol 167: 1198-1203.
62. Aziz KA, Till KJ, Zuzel M, Cawley JC (2000) Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia. Blood 96: 3161-3167.
63. Corjay MH, Kearney MA, Munzer DA, Diamond SM, Stoltenborg JK (1998) Antiproliferative gene BTG1 is highly expressed in apoptotic cells in macrophage-rich areas of advanced lesions in Watanabe heritable hyperlipidemic rabbit and human. Lab Invest 78: 847-858.
64. van Golen CM, Soules ME, Grauman AR, Feldman EL (2003) N-Myc overexpression leads to decreased beta1 integrin expression and increased apoptosis in human neuroblastoma cells. Oncogene 22: 2664-2673.
65. Gendron S, Couture J, Aoudjit F (2003) Integrin alpha2beta1 inhibits Fasmediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem 278: 48633-48643.
66. Kim S, Bakre M, Yin H, Varner JA (2002) Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 110: 933-941.
67. Faraldo MM, Deugnier MA, Lukashev M, Thiery JP, Glukhova MA (1998) Perturbation of beta1-integrin function alters the development of murine mammary gland. EMBO J 17: 2139-2147.
68. Vlahakis NE, Young BA, Atakilit A, Hawkridge AE, Issaka RB, et al. (2007) Integrin alpha9beta1 directly binds to vascular endothelial growth factor (VEGF)-A and contributes to VEGF-A-induced angiogenesis. J Biol Chem 282: 15187-15196.
69. Takahashi H, Isobe T, Horibe S, Takagi J, Yokosaki Y, et al. (2000) Tissue transglutaminase, coagulation factor XIII, and the pro-polypeptide of von Willebrand factor are all ligands for the integrins alpha 9beta 1 and alpha 4beta 1. J Biol Chem 275: 23589-23595.
70. Lobov IB, Brooks PC, Lang RA (2002) Angiopoietin-2 displays VEGFdependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 99: 11205-11210.
71. Evert BO, Wullner U, Klockgether T (2000) Cell death in polyglutamine diseases. Cell Tissue Res 301: 189-204.
72. Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, et al. (2006) Genespecific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev 20: 601-612.
73. Kaiser RA, Bueno OF, Lips DJ, Doevendans PA, Jones F, et al. (2004) Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo. J Biol Chem 279: 15524-15530.
74. Silva G, Cunha A, Gregoire IP, Seldon MP, Soares MP (2006) The antiapoptotic effect of heme oxygenase-1 in endothelial cells involves the degradation of p38 alpha MAPK isoform. J Immunol 177: 1894-1903.
75. Nagata Y, Todokoro K (1999) Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. Blood 94: 853-863.
76. Sabourin LA, Rudnicki MA (1999) Induction of apoptosis by SLK, a Ste20-related kinase. Oncogene 18: 7566-7575.
77. Rots NY, Liu M, Anderson EC, Freedman LP (1998) A differential screen for ligand-regulated genes: identification of HoxA10 as a target of vitamin D3 induction in myeloid leukemic cells. Mol Cell Biol 18: 1911-1918.